Yangbo Lv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yangbo Lv has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Jian-Guang Xu
2 shared publicationsLi-Hui Wang
2 shared publicationsShui-Quan Lin
2 shared publicationsXiao Zhu
Department of Gastroenterology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou 324002, China
2 shared publications- Haibin Tong
College of Life and Environmental Science, Wenzhou University, Wenzhou 325000, China; State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing 100700, China
1 shared publication Hongye Mb Yao
The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 15 July 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 17 (7)
Nav1.6 drives colorectal cancer proliferation and invasion through MAPK signaling pathway
BACKGROUND Voltage-gated sodium channels (VGSCs, or Navs) are highly expressed in various tumors and play a critical role in tumor metastasis and invasion. AIM To identify Nav1.6-associated cancer genes through bioinformatics analysis and experimental validation, with the goal of determining the role of Nav1.6 in colorectal cancer (CRC) metastasis. METHODS The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) data were analyzed using weighted correlation network analysis (WGCNA) and Venn analysis to identify Nav1.6-associated genes in CRC. siRNA, real-time PCR, and western blotting were employed to validate the Nav1.6-associated cancer genes and signaling pathways identified in CRC. Cell counting kit-8 and Transwell migration assays were used to assess the proliferation and migration of CRC cells. RESULTS The analysis of TCGA and GEO datasets, along with WGCNA, identified 575 differentially expressed genes associated with SCN8A (Nav1.6) in CRC, which were particularly enriched in MAPK signaling pathways. Tissue microarray analysis of surgical samples revealed elevated Nav1.6 levels in CRC tissues, which were predominantly in the cytoplasm and nucleus rather than in the membrane. Cytoplasmic Nav1.6 expression increased with T stage increases, consistent with the TCGA findings. SCN8A knockdown in colon tumor cells significantly reduced cell proliferation and invasion and downregulated key proteins in the RAF-MAPK pathway. CONCLUSION These findings suggest that Nav1.6 promotes CRC cell proliferation and invasion which is related to the MAPK signaling pathway.
- 15 July 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 17 (7)
Open AccessNav1.6 drives colorectal cancer proliferation and invasion through MAPK signaling pathway
BACKGROUND Voltage-gated sodium channels (VGSCs, or Navs) are highly expressed in various tumors and play a critical role in tumor metastasis and invasion. AIM To identify Nav1.6-associated cancer genes through bioinformatics analysis and experimental validation, with the goal of determining the role of Nav1.6 in colorectal cancer (CRC) metastasis. METHODS The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) data were analyzed using weighted correlation network analysis (WGCNA) and Venn analysis to identify Nav1.6-associated genes in CRC. siRNA, real-time PCR, and western blotting were employed to validate the Nav1.6-associated cancer genes and signaling pathways identified in CRC. Cell counting kit-8 and Transwell migration assays were used to assess the proliferation and migration of CRC cells. RESULTS The analysis of TCGA and GEO datasets, along with WGCNA, identified 575 differentially expressed genes associated with SCN8A (Nav1.6) in CRC, which were particularly enriched in MAPK signaling pathways. Tissue microarray analysis of surgical samples revealed elevated Nav1.6 levels in CRC tissues, which were predominantly in the cytoplasm and nucleus rather than in the membrane. Cytoplasmic Nav1.6 expression increased with T stage increases, consistent with the TCGA findings. SCN8A knockdown in colon tumor cells significantly reduced cell proliferation and invasion and downregulated key proteins in the RAF-MAPK pathway. CONCLUSION These findings suggest that Nav1.6 promotes CRC cell proliferation and invasion which is related to the MAPK signaling pathway.
- Open Access
- 20 June 2025
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 12 (8) , 100247
Refining the evidence linking dietary diversity, genetic susceptibility, and dementia
- 20 June 2025
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 12 (8) , 100247
Open AccessRefining the evidence linking dietary diversity, genetic susceptibility, and dementia
- Open Access
- 22 April 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Open
- Vol. 63 (3) , 240-241
A commentary on ‘Cold scissors ploughing technique versus electrosurgical excision for hysteroscopic adhesiolysis: a multicenter randomized controlled trial’
- 22 April 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Open
- Vol. 63 (3) , 240-241
Open AccessA commentary on ‘Cold scissors ploughing technique versus electrosurgical excision for hysteroscopic adhesiolysis: a multicenter randomized controlled trial’
- Open Access
- 12 September 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1409627
Biomarkers of lymph node metastasis in colorectal cancer: update
Colorectal cancer (CRC) ranks as the second leading cause of cancer-related deaths globally, trailing only behind lung cancer, and stands as the third most prevalent malignant tumor, following lung and breast cancers. The primary cause of mortality in colorectal cancer (CRC) stems from distant metastasis. Among the various routes of metastasis in CRC, lymph node metastasis predominates, serving as a pivotal factor in both prognostication and treatment decisions for patients. This intricate cascade of events involves multifaceted molecular mechanisms, highlighting the complexity underlying lymph node metastasis in CRC. The cytokines or proteins involved in lymph node metastasis may represent the most promising lymph node metastasis markers for clinical use. In this review, we aim to consolidate the current understanding of the mechanisms and pathophysiology underlying lymph node metastasis in colorectal cancer (CRC), drawing upon insights from the most recent literatures. We also provide an overview of the latest advancements in comprehending the molecular underpinnings of lymph node metastasis in CRC, along with the potential of innovative targeted therapies. These advancements hold promise for enhancing the prognosis of CRC patients by addressing the challenges posed by lymph node metastasis.
- 12 September 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1409627
Open AccessBiomarkers of lymph node metastasis in colorectal cancer: update
Colorectal cancer (CRC) ranks as the second leading cause of cancer-related deaths globally, trailing only behind lung cancer, and stands as the third most prevalent malignant tumor, following lung and breast cancers. The primary cause of mortality in colorectal cancer (CRC) stems from distant metastasis. Among the various routes of metastasis in CRC, lymph node metastasis predominates, serving as a pivotal factor in both prognostication and treatment decisions for patients. This intricate cascade of events involves multifaceted molecular mechanisms, highlighting the complexity underlying lymph node metastasis in CRC. The cytokines or proteins involved in lymph node metastasis may represent the most promising lymph node metastasis markers for clinical use. In this review, we aim to consolidate the current understanding of the mechanisms and pathophysiology underlying lymph node metastasis in colorectal cancer (CRC), drawing upon insights from the most recent literatures. We also provide an overview of the latest advancements in comprehending the molecular underpinnings of lymph node metastasis in CRC, along with the potential of innovative targeted therapies. These advancements hold promise for enhancing the prognosis of CRC patients by addressing the challenges posed by lymph node metastasis.
- Open Access
- 31 March 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (10) , 11641-11650
Impacts of pre‐existing diabetes mellitus on colorectal cancer in a mice model
Background: Although diabetes mellitus (DM) is regarded as a risk factor of colorectal cancer (CRC), the impacts of pre‐existing DM on CRC without drug intervention remain unknown. The purpose of this study was to investigate and analyze the effects of diabetes mellitus (DM) on colorectal cancer (CRC). And, to further explore the influencing factors and the mechanisms of DM affects CRC progression.Methods: In this study, we investigated the effects of DM on CRC progression in a streptozotocin‐induced DM mice model. Furthermore, we evaluated the change of T cells levels using flow cytometry and indirect immunofluorescence. We assessed the alternation of gut microbiome and the transcriptional response using 16s rRNA sequencing and RNA‐seq.Results: Results showed that the mice survival time was significantly decreased in CRC complicated with DM group (DM‐CRC), compared with only tumor bearing mice (CRC group). Furthermore, we found that DM could affect the immune response by changing the infiltration of CD4+ T cells, CD8+ T cells and mucosal‐associated invariant T cell (MAIT) in the CRC progression. In addition, DM could induce gut microbiome dysbiosis and change the transcriptional response in CRC complicated with DM.Conclusion: For the first time, the effects of DM on CRC were systematically characterized in a mice model. Our findings highlight the effects of pre‐existing DM on CRC, and these findings should facilitate further studies in exploring and developing potentially targeted therapy for CRC in diabetic patients. Our results suggest that the effects induced by DM should be considered in the treatment for CRC complicated with DM patients.
- 31 March 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (10) , 11641-11650
Open AccessImpacts of pre‐existing diabetes mellitus on colorectal cancer in a mice model
Background: Although diabetes mellitus (DM) is regarded as a risk factor of colorectal cancer (CRC), the impacts of pre‐existing DM on CRC without drug intervention remain unknown. The purpose of this study was to investigate and analyze the effects of diabetes mellitus (DM) on colorectal cancer (CRC). And, to further explore the influencing factors and the mechanisms of DM affects CRC progression.Methods: In this study, we investigated the effects of DM on CRC progression in a streptozotocin‐induced DM mice model. Furthermore, we evaluated the change of T cells levels using flow cytometry and indirect immunofluorescence. We assessed the alternation of gut microbiome and the transcriptional response using 16s rRNA sequencing and RNA‐seq.Results: Results showed that the mice survival time was significantly decreased in CRC complicated with DM group (DM‐CRC), compared with only tumor bearing mice (CRC group). Furthermore, we found that DM could affect the immune response by changing the infiltration of CD4+ T cells, CD8+ T cells and mucosal‐associated invariant T cell (MAIT) in the CRC progression. In addition, DM could induce gut microbiome dysbiosis and change the transcriptional response in CRC complicated with DM.Conclusion: For the first time, the effects of DM on CRC were systematically characterized in a mice model. Our findings highlight the effects of pre‐existing DM on CRC, and these findings should facilitate further studies in exploring and developing potentially targeted therapy for CRC in diabetic patients. Our results suggest that the effects induced by DM should be considered in the treatment for CRC complicated with DM patients.